- Conditions
- Multiple Sclerosis
- Interventions
- Ponesimod, Placebo
- Drug · Other
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 431
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- Tecfidera
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Rebif®, Copaxone®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Remibrutinib (Open Label)
- Drug
- Lead sponsor
- Moein Amin
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Tolebrutinib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Cullman, Alabama • Maitland, Florida • Tampa, Florida + 5 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
- Interventions
- Tovaxin
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 27
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
- Conditions
- Multiple Sclerosis
- Interventions
- LY3541860, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting
- Interventions
- Remibrutinib, Ocrelizumab (US)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Interventions
- estriol, Placebo, Norethindrone, Progestin Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- No intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- San Francisco, California • Smyrna, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
- Interventions
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Pediatric Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 1,276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 60 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
- Drug
- Lead sponsor
- Revalesio Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- John F. Foley, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Sclerosis
- Interventions
- Glatiramer acetate
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Sclerosis
- Interventions
- fingolimod
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 42
- States / cities
- Cullman, Alabama • Berkeley, California • Pasadena, California + 36 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Placebo, Ocrelizumab, Avonex
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
- Conditions
- Multiple Sclerosis (MS) Relapsing Remitting
- Interventions
- Vumerity, Tecfidera
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
- Interventions
- Cionic Neural Sleeve NS-100, Walking Program
- Device · Behavioral
- Lead sponsor
- Cionic, Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Rebif, Tecfidera
- Drug
- Lead sponsor
- IMS HEALTH GmbH & Co. OHG
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more